Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506457 | 0.77 | CNR1 (0.44) | KDM4ECNR2POLBALDH1A1LMNA | |
| SCHEMBL1849497 | 0.75 | CRHR1 (0.52) | CRHR1KDM4ECNR2GAAPOLB | |
| SCHEMBL1849496 | 0.75 | CRHR1 (0.52) | CRHR1KDM4ECNR2GAAPOLB | |
| SCHEMBL3786349 | 0.74 | KDM4E (0.41) | KDM4EPOLBALDH1A1LMNATSHR | |
| SCHEMBL21780683 | 0.73 | CRHR1 (0.57) | CRHR1KDM4EGAAPOLBTGFBR1 | |
| SCHEMBL12506476 | 0.72 | TGFBR1 (0.39) | KDM4ETGFBR1ALDH1A1 | |
| SCHEMBL19105610 | 0.72 | CRHR1 (0.41) | CRHR1CNR2GAATGFBR1ALDH1A1 | |
| SCHEMBL2686357 | 0.72 | AKR1C3 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL24758363 | 0.72 | GAA (0.44) | CRHR1KDM4ECNR2GAAHTR2C | |
| SCHEMBL2684765 | 0.72 | CRHR1 (0.46) | CRHR1CNR2GAAPOLBTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, OPRM1, OPRK1 | CRHR1 101/4885KDM4E 2768/4885CNR2 7/4885 |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | CRHR1 115/4885KDM4E 3018/4885CNR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.